Get the Stockscreener App
6.57
0.92%
0.06
After Hours:
6.51
-0.06
-0.91%
Bioventus Inc stock is traded at $6.57, with a volume of 238.53K.
It is up +0.92% in the last 24 hours and down -9.13% over the past month.
Bioventus Inc is a medical technology company. The company is engaged in developing and commercializing clinically differentiated treatments that engage and enhance the body's natural healing process. It offers a diverse portfolio of products to serve physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine and neurosurgery. Its portfolio of products is grouped into three verticals based on clinical use: Pain Treatments, Surgical Solutions, and Restorative Therapies. Geographical presence is in the United States which derives key revenue, and International markets.
See More
Previous Close:
$6.51
Open:
$6.59
24h Volume:
238.53K
Relative Volume:
0.60
Market Cap:
$439.48M
Revenue:
$555.06M
Net Income/Loss:
$-39.48M
P/E Ratio:
-10.95
EPS:
-0.6
Net Cash Flow:
$29.05M
1W Performance:
-3.24%
1M Performance:
-9.13%
6M Performance:
-12.17%
1Y Performance:
-45.84%
1-Day Range:
$6.51
$6.65
1-Week Range:
$6.37
$6.83
52-Week Range:
$5.81
$14.38
Bioventus Inc Stock (BVS) Company Profile
Name
Bioventus Inc
Sector
Industry
Phone
(919) 474-6700
Address
4721 EMPEROR BOULEVARD, SUITE 100, DURHAM
Compare BVS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BVS
Bioventus Inc
|
6.57 | 435.47M | 555.06M | -39.48M | 29.05M | -0.60 |
|
ABT
Abbott Laboratories
|
131.38 | 230.73B | 43.11B | 13.94B | 6.78B | 7.9963 |
|
BSX
Boston Scientific Corp
|
94.95 | 141.37B | 18.49B | 2.50B | 3.49B | 1.6801 |
|
SYK
Stryker Corp
|
364.92 | 139.39B | 23.82B | 2.92B | 4.02B | 7.5574 |
|
MDT
Medtronic Plc
|
95.58 | 122.43B | 34.20B | 4.69B | 5.30B | 3.6218 |
|
EW
Edwards Lifesciences Corp
|
72.95 | 43.41B | 5.69B | 1.41B | 577.90M | 6.9828 |
Bioventus Inc Stock (BVS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-07-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-17-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Dec-07-23 | Upgrade | Canaccord Genuity | Hold → Buy |
| Aug-09-23 | Upgrade | Craig Hallum | Hold → Buy |
| Nov-22-22 | Downgrade | Craig Hallum | Buy → Hold |
| Nov-09-22 | Downgrade | Canaccord Genuity | Buy → Hold |
| Nov-09-22 | Downgrade | JP Morgan | Overweight → Underweight |
| Mar-15-22 | Initiated | Craig Hallum | Buy |
| Nov-15-21 | Resumed | Morgan Stanley | Overweight |
| Nov-10-21 | Resumed | JP Morgan | Overweight |
| Jul-01-21 | Downgrade | Goldman | Buy → Neutral |
| Mar-08-21 | Initiated | Canaccord Genuity | Buy |
| Mar-08-21 | Initiated | Goldman | Buy |
| Mar-08-21 | Initiated | JP Morgan | Overweight |
| Mar-08-21 | Initiated | Morgan Stanley | Overweight |
View All
Bioventus Inc Stock (BVS) Latest News
Head-To-Head Comparison: Vyome (NASDAQ:HIND) vs. Bioventus (NASDAQ:BVS) - Defense World
Head-To-Head Survey: Bioventus (NASDAQ:BVS) & Shoulder Innovations (NYSE:SI) - Defense World
Analyzing TranS1 (OTCMKTS:BAXSQ) and Bioventus (NASDAQ:BVS) - Defense World
Analyzing recovery setups for Bioventus Inc. investorsM&A Rumor & Weekly High Conviction Ideas - newser.com
Bioventus Inc. stock retracement – recovery analysisWeekly Investment Recap & Fast Entry Momentum Trade Alerts - newser.com
Bioventus (NASDAQ:BVS) Earns "Sell (D-)" Rating from Weiss Ratings - MarketBeat
What technical models suggest about Bioventus Inc.’s comebackJuly 2025 Update & Expert Curated Trade Ideas - newser.com
Full technical analysis of Bioventus Inc. stockMarket Performance Recap & Real-Time Volume Trigger Notifications - newser.com
Is Bioventus Inc a good long term investmentSwing Trading Ideas & Rapid Capital Gain - earlytimes.in
290,700 Shares in Bioventus Inc. $BVS Acquired by Knights of Columbus Asset Advisors LLC - MarketBeat
Multi factor analysis applied to Bioventus Inc.Earnings Summary Report & Breakout Confirmation Trade Signals - newser.com
Volatility clustering patterns for Bioventus Inc.Quarterly Portfolio Summary & Daily Oversold Stock Bounce Ideas - newser.com
Can Bioventus Inc. hit a new high this monthPortfolio Value Report & Technical Pattern Alert System - newser.com
How Bioventus Inc. stock benefits from strong dollarPortfolio Update Summary & Reliable Intraday Trade Plans - newser.com
Using Bollinger Bands to evaluate Bioventus Inc.Trade Analysis Summary & Free Fast Gain Swing Trade Alerts - newser.com
Forecasting Bioventus Inc. price range with options data2025 Breakouts & Breakdowns & Intraday High Probability Alerts - newser.com
Bioventus Inc Stock Analysis and ForecastBear Market Strategies & In-Depth Analyst Ratings Explained Simply - earlytimes.in
What drives Bioventus Inc stock priceBreakout Stock Watch & Small Investment Portfolio Growth - earlytimes.in
PetVivo (NASDAQ:PETV) versus Bioventus (NYSE:BVS) Head-To-Head Comparison - Defense World
Comparing Bioventus Inc. in custom built stock radarsProduct Launch & Fast Entry Momentum Alerts - newser.com
Comparing Bioventus (NYSE:BVS) and Retractable Technologies (NYSE:RVP) - Defense World
Orthobiologics Market May See a Big Move | Major Giants Medtronic, Zimmer Biomet, Bioventus - newstrail.com
Is Bioventus Inc. building a consolidation baseTreasury Yields & Weekly Chart Analysis and Trade Guides - newser.com
Bioventus (NYSE:BVS) Shares Gap DownHere's What Happened - MarketBeat
Bioventus Inc. stock daily chart insightsBull Run & Technical Pattern Recognition Alerts - newser.com
Craig-Hallum Maintains Bioventus(BVS.US) With Buy Rating - 富途牛牛
Should You Be Worried About Bioventus Inc.'s (NASDAQ:BVS) 1.3% Return On Equity? - Yahoo Finance
Bioventus Inc Stock (BVS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Bioventus Inc Stock (BVS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Bartholdson John A. | Director |
Jun 02 '25 |
Option Exercise |
0.00 |
26,493 |
0 |
72,045 |
| SUTTER MARTIN P | Director |
Jun 02 '25 |
Option Exercise |
0.00 |
26,493 |
0 |
85,241 |
| STALNECKER SUSAN M | Director |
Jun 02 '25 |
Option Exercise |
0.00 |
26,493 |
0 |
105,957 |
| NOHRA GUY P | Director |
Jun 02 '25 |
Option Exercise |
0.00 |
26,493 |
0 |
126,610 |
| NEELS GUIDO J | Director |
Jun 02 '25 |
Option Exercise |
0.00 |
26,493 |
0 |
85,241 |
| McMurry-Heath Michelle | Director |
Jun 02 '25 |
Option Exercise |
0.00 |
26,493 |
0 |
74,698 |
| Ladone Mary Kay | Director |
Jun 02 '25 |
Option Exercise |
0.00 |
26,493 |
0 |
78,981 |
| HAWKINS WILLIAM A | Director |
Jun 02 '25 |
Option Exercise |
0.00 |
26,493 |
0 |
257,851 |
| Beyer Pat | Director |
Jun 02 '25 |
Option Exercise |
0.00 |
26,493 |
0 |
76,436 |
| Singleton Mark Leonard | SVP & CFO |
Apr 11 '25 |
Sale |
7.57 |
3,875 |
29,334 |
141,088 |
0.01%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):